Forte Biosciences (FBRX) Common Equity (2016 - 2026)
Forte Biosciences' Common Equity was $183.79 million in Q2 2026, up 86.4% from $98.61 million a year earlier and up 336.6% from the prior quarter.
Forte Biosciences (FBRX) Common Equity (2016 - 2026) Analysis & Trends
At the end of FY2025, Common Equity at Forte Biosciences came in at $60.99 million, up 16.2% from FY2024.
- Common Equity shows a five-year compound annual growth rate of 0.7% (FY2020 to FY2025).
- In earlier years, Common Equity was $52.48 million in FY2024 (+48.6%), $35.31 million in FY2023 (-9.0%), $38.82 million in FY2022 (-6.6%) and $41.55 million in FY2021 (-29.6%).
- The Q2 2026 figure marks the highest quarterly Common Equity in data going back to Q4 2016.
- Compared with a year earlier, Common Equity has increased for seven straight quarters, with growth averaging 174.7% over the last eight quarters.
- The best year-over-year quarter for Common Equity over five years was Q3 2025 (growth of 797.9%); the worst was Q3 2024 (a decline of 76.8%).
- Per Business Quant data, FBRX's Common Equity in the three quarters before Q2 2026 was $42.1 million (Q1 2026), $60.99 million (Q4 2025) and $84.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 41.98 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 20.25 Bn |
| 10 | Forte Biosciences | 1.58 Bn | 1.38 Bn | - | 183.79 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 183.79 Mn |
| Mar 31, 2026 | 42.10 Mn |
| Dec 31, 2025 | 60.99 Mn |
| Sep 30, 2025 | 84.10 Mn |
| Jun 30, 2025 | 98.61 Mn |
| Mar 31, 2025 | 38.43 Mn |
| Dec 31, 2024 | 52.48 Mn |
| Sep 30, 2024 | 9.37 Mn |
| Jun 30, 2024 | 16.96 Mn |
| Mar 31, 2024 | 28.69 Mn |
| Dec 31, 2023 | 35.31 Mn |
| Sep 30, 2023 | 40.41 Mn |
| Jun 30, 2023 | 24.88 Mn |
| Mar 31, 2023 | 32.95 Mn |
| Dec 31, 2022 | 38.82 Mn |
| Sep 30, 2022 | 42.84 Mn |
| Jun 30, 2022 | 38.21 Mn |
| Mar 31, 2022 | 40.05 Mn |
| Dec 31, 2021 | 41.55 Mn |
| Sep 30, 2021 | 43.65 Mn |
Forte Biosciences Common Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=common-equity&ticker=FBRX&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "common-equity", "ticker": "FBRX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=common-equity&ticker=FBRX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();